A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis

Sang Eun Yoon 1 · Seok Jin Kim 1 · Dok Hyun Yoon 2 · Youngil Koh 3 · Yeung-Chul Mun 4 · Young Rok Do 5 · Yoon Seok Choi 6 · Deok Hwan Yang 7 · Min Kyoung Kim 8 · Gyeong-Won Lee 9 · Cheolwon Suh 2 · Young Hyeh Ko 10 · Won Seog Kim 1

Received: 31 October 2019 / Accepted: 12 March 2020
© The Author(s) 2020

Abstract
Epstein-Barr virus (EBV) positivity in diffuse large B cell lymphoma (DLBCL) provokes a critical oncogenic mechanism to activate intracellular signaling by LMP1. LMP1 specifically mimics the role of BTK-dependent B cell receptor. Therefore, a trial considering RCHOP therapy along with ibrutinib (I-RCHOP) in combination was conducted among patients with EBV-positive DLBCL. This study was an open-label, single-arm, prospective multicenter phase II clinical trial. Patients received 560 mg of ibrutinib with RCHOP every 3 weeks until 6 cycles were completed or progression or unacceptable toxicity was observed. The primary endpoint was objective response, while secondary endpoints included toxicity, progression-free survival, and overall survival. A matched case-control analysis was completed to compare the efficacy and toxicity of I-RCHOP and RCHOP, respectively, in EBV-positive DLBCL patients. From September 2016 to August 2019, 24 patients proven to have EBV-positive DLBCL in the tissue were enrolled and received I-RCHOP. Their median age was 58 years (range, 28–84 years). The objective overall response was 66.7%, including 16 patients who achieved complete response after 6 cycles. Patients aged younger than 65 years presented a superior OR (87.5%) as compared with those older than 65 years (25.0%; \( p = 0.01 \)). In a matched case-control study, I-RCHOP therapy provoked a more favorable complete response rate (87.3%) than did RCHOP (68.8%) in those younger than 65 years. Treatment-related mortality was linked most frequently with I-RCHOP therapy (four patients presented with unusual infection without Gr3/4 neutropenia) in the older age group (age \( \geq 65 \) years). In conclusion, in this phase II trial for EBV-positive DLBCL, I-RCHOP was effective but did not show a significant improvement in response and survival in comparison with RCHOP. Also, I-RCHOP promoted serious toxicity and treatment-related death in older patients.

Keywords Ibrutinib · R-CHOP · Epstein-Barr virus-positive · Diffuse large B cell lymphoma

Introduction
Epstein-Barr virus (EBV)-positive, diffuse large B cell lymphoma (DLBCL) is an EBV-positive, monoclonal, large B cell lymphoproliferative disorder mainly seen in individuals older than 50 years of age [1, 2]. Previous studies have shown that EBV-positive DLBCL is mainly correlated with high-intermediate/high International Prognostic Index (IPI) scores, advanced disease stage (III/IV) at diagnosis, and inferior outcomes in comparison with EBV-negative DLBCL [3, 4].

EBV-infected cells encode eight EBV-encoded latent genes consisting of six EBV-encoded nuclear antigens (EBNAs) and
two latent membrane proteins (LMP1 and LMP2) [5]. LMP1 and LMP2 in particular behave like B cell receptor (BCR)-mediated Akt, which is dependent upon spleen tyrosine kinase and Bruton’s tyrosine kinase (BTK). These tyrosine kinases contribute to enhanced cellular proliferation and survival signaling such as the nuclear factor-kappa B (NF-κB) and phosphoinositide 3-kinase (PI3K/Akt) pathways [6]. In our experiment, we transfected vector-encoding LMP1 or LMP1_delCTAR1 (C-terminal-activating region 1) and LMP1_delCTAR2 into a DLBCL cell line and observed the BCR signaling pathway (Supplementary Materials and methods). As a result, the BTK signaling pathway was activated when LMP1 was expressed. It was also confirmed that the CTAR1 of LMP1 was an important domain for BTK activation. In addition, cell viability was decreased when the BTK inhibitor (ibrutinib) was treated with LMP1-expressing cells (Supplementary Fig. S1). Based on previous studies that proved the efficacy of rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone (RCHOP) therapy combined with ibrutinib (I-RCHOP), we designed this study to boost the anti-tumor effect of EBV-positive DLBCL [7, 8]. Here, we report the results of an open-label, multicenter phase II study that investigated the combination ibrutinib and RCHOP for EBV-positive DLBCL using a matched case-control study.

Patients and methods

Study design and treatment

This study was an open-label, single-arm, prospective multicenter clinical trial for evaluating the efficacy and toxicity of I-RCHOP in subjects with newly diagnosed, chemotherapy-naïve, EBV-positive DLBCL. We defined EBV positivity as a finding of 20% or more of EBV-encoded RNA in situ hybridization–positive tumor cells among total tumor cells during pathology evaluation [2]. Ibrutinib (560 mg/day) was administrated orally and RCHOP (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (maximum total of 2 mg) on day 1 and oral prednisone 100 mg on days 1–5) therapy was administered intravenously every 21 days, respectively, until the end of 6 cycles or progression or unacceptable toxicity were observed.

Patient eligibility

Patients had to fulfill the following criteria to be included in this research: (1) histologically confirmed EBV-positive DLBCL without central nervous system involvement; (2) aged 19 years or older; (3) no previous treatment for DLBCL, although we allowed the usage of prednisolone 100 mg or equivalent dosage of any type of steroid (for a maximum of 7 days) and radiation for reducing symptoms related with mass effect; (4) one or more measurable lesions; (5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; and (6) adequate organ function. The exclusion criteria included any life-threatening illness, medical condition, or organ system dysfunction that could compromise the subject’s safety, according to the investigator’s opinion. Written informed consent was obtained from each patient prior to study enrollment. This study was approved by the institutional review board of each institution and conducted in accordance with the tenets of the Declaration of Helsinki. This trial was registered at www.ClinicalTrials.gov as NCT02670616.

Matched case-control study design

In addition, we organized a case-control study to figure out the superiority (e.g., overall response rate, toxicity) of RCHOP (control) and I-RCHOP (case) in EBV-positive DLBCL. To serve as matched controls, we selected EBV-positive DLBCL patients who received only RCHOP chemotherapy from 2006 to 2018 as part of Samsung Medical Center’s prospective lymphoma registry (Fig. 1b). Especially, we employed strict matching categories, which were age, ECOG performance status, IPI score, and Ann Arbor stage (Supplementary Table S1).

Study endpoints

The primary endpoint of this research was the objective response rate (ORR) based on the proportion of complete response (CR) and partial response (PR). Secondary endpoints included toxicity, progression-free survival (PFS), and overall survival (OS). Adverse events (AEs) were assessed according to the Common Terminology Criteria for Adverse Events version 4.0.

Assessment

In study participants, complete blood count, organ function (i.e., creatinine, aspartate transaminase, alanine transaminase), EBV DNA titer, electrocardiogram (ECG), transthoracic echocardiogram (TTE), and measurable lesions were assessed with computed tomography (CT) scans of the neck, chest, and abdominal pelvis or 18F-fluorodeoxyglucose positron-emission tomography (PET)/CT scans at before enrollment, during treatment, and at the end of treatment. We assessed response according to the Lugano response criteria for non-Hodgkin’s lymphoma [9].
Statistical analyses

The aforementioned previous study with EBV-positive DLBCL revealed a 50% complete response rate was achieved by RCHOP without the use of ibrutinib [1]. Separately, the phase I clinical trial with DLBCL patients who received ibrutinib (560 mg/day) in conjunction with RCHOP presented a 95% overall response rate, including both cases of CR and PR [10]. From these results, we hypothesized that the complete response rate of EBV-positive DLBCL might be up to 80% when ibrutinib and RCHOP were combined. Thus, if we could achieve complete response in 14 out of 21 patients, we could rule that our new regimen might be effective for this disorder and likely could start further investigations such as phase I/II trials (P0 = 50%, one-sided alpha = 5%, P1 = 80%, statistical power = 90%) [11]. Considering a 10% rate of interruption, a total of 24 patients were included.

Statistical analyses were performed using the IBM PASW version 24.0 software program (SPSS Inc., Chicago, IL, USA). In the scheme to demonstrate the superiority of I-RCHOP and RCHOP, descriptive statistics was reported as proportions and medians, and intergroup comparisons were achieved using Fisher’s exact test for categorical variables.

In addition, survival curves were achieved using the Kaplan-Meier method, and the comparison of survival rates was calculated with the log-rank test. Univariate and multivariate analyses for the assessment of predictive values of I-RCHOP were completed using Cox’s regression model. A two-sided p value of less than 0.05 was considered to be statistically significant.

Results

Patient characteristics

Between September 2016 and August 2019, 24 patients were enrolled from 10 institutes. The cutoff date for analysis was March 2019, and the median follow-up period was 7.9 months, with six death events (25%). Sixteen patients (67%) finished 6 cycles of chemotherapy. In the 48 patients who were confirmed to have EBV-positive DLBCL at Samsung Medical Center for the purpose of the matched case-control study, baseline clinical characteristics were balanced comparatively among both the I-RCHOP (n = 24) and RCHOP (n = 24) groups (Table 1). The median ages were 58 years (range,

Table 1 Baseline characteristics of EBV-positive DLBCL patients according to I-RCHOP and RCHOP alone

| Variable                         | I-RCHOP (n = 24) | RCHOP (n = 24) | p value |
|----------------------------------|-----------------|---------------|---------|
| Sex, no. (%)                     |                 |               |         |
| Male                             | 17 (70.8)       | 12 (50.0)     | 0.24    |
| Female                           | 7 (29.2)        | 12 (50.0)     |         |
| Age                              |                 |               |         |
| Median (range)                   | 58 (28–84)      | 57 (26–82)    |         |
| Older than 60 years              | 10 (41.7)       | 10 (41.7)     | 1.00    |
| Older than 70 years              | 6 (25.0)        | 6 (25.0)      | 1.00    |
| Performance status, no. (%)      |                 |               |         |
| ECOG 0–1                         | 21 (87.5)       | 21 (87.5)     | 1.00    |
| ECOG ≥ 2                         | 3 (12.5)        | 3 (12.5)      |         |
| IPI risk group, no. (%)          |                 |               |         |
| Low/low-intermediate             | 7 (29.2)        | 6 (25.0)      | 1.00    |
| High-intermediate/high           | 17 (70.8)       | 18 (75.0)     |         |
| Histologic subtype, no. (%)      |                 |               |         |
| ABC type                         | 11 (45.8)       | 9 (37.5)      | 0.38    |
| GCB type                         | 8 (33.3)        | 5 (20.8)      |         |
| Not evaluated                    | 5 (20.8)        | 10 (41.7)     |         |
| Elevated LDH, no. (%)            | 19 (79.2)       | 23 (95.8)     | 0.19    |
| BM involvement, no. (%)          | 1 (4.2)         | 4 (16.7)      | 0.35    |
| Ann Arbor stage, no. (%)         |                 |               |         |
| I–II                             | 7 (29.2)        | 6 (25.0)      | 1.00    |
| III–IV                           | 17 (70.8)       | 18 (75.0)     |         |
| Detection of EBV DNA in serum, no. (%) | 8 (33.3) | 9 (37.5) | 0.18 |
| Patients who finished 6 cycles no. (%) | 16 (66.7) | 17 (70.8%) | 1.00 |

ECOG Eastern Cooperative Oncology Group, LDH lactic dehydrogenase, IPI International Prognostic Index, ABC activated B cell, GCB germinal B cell
28–84 years) in I-RCHOP and 57 years (range, 26–82 years) in RCHOP. In both groups, approximately 70% of patients equally presented with high-intermediate/high IPI scores; in addition, more than half patients presented with Ann Arbor stages III or IV.

**Response**

The ORR of I-RCHOP was 66.7% (n = 16). The most common cause for treatment interruption was AEs (n = 5; 21%), followed by disease progression (n = 3; 12.5%) (Fig. 1a). Among the I-RCHOP patients, who displayed a 66.7% ORR, those aged younger than 65 years (87.5%) achieved a superior ORR than did those older than 65 years (25.0%; p = 0.01; Table 2). When comparing with findings of the matched case-control group, for all patients aged younger than 65 years, though there was a higher CR rate for I-RCHOP (87.3% vs. 68.8%), the ORR (87.5% vs. 75.0%; p = 0.69) between I-RCHOP and RCHOP did not show a significant difference. In the patients older than 65 years of age, 50% of patients in the I-RCHOP group dropped out previously due to unacceptable toxicities before the end of the treatment period; thus, the response rate was superior in patients who received RCHOP (50.0% vs. 25.0%; p = 0.81; Table 3).

**Toxicity**

Across I-RCHOP and RCHOP, most patients older than 65 years of age in I-RCHOP group could not complete 6 cycles of chemotherapy (I-RCHOP, 87.5% vs. 25.0%; RCHOP 81.3% vs. 50.0%) due to grades 3/4 AEs (I-RCHOP, 40.0% vs. 82.5%; RCHOP, 75.0% vs. 75.0%). In addition, there were not any EBV reactivation case. In the patients who received I-RCHOP, there were four treatmen

**Survival**

Median PFS (20.6 months, 95% CI non-evaluable vs. 35.3 months, 95% CI 0.0–86.9; p = 0.46) and median OS (20.9 months, 95% CI 0.6–41.2 vs. 48.1 months, 95% CI NR; p = 0.72) according to I-RCHOP and RCHOP were not significantly different (Fig. 2a and b). Based on the one-year survival analysis, one-year OS (33.3% vs. 58.3%; p = 0.15) and PFS (29.2% vs. 36.8%, p = 0.24) were not correlated with more favorable outcomes in I-RCHOP than in RCHOP among all patients. In line with age-based case-control comparisons, in patients aged younger than 65 years, the median PFS (NR vs. 92.2 months, 95% CI 9.8–176.0; p = 0.68) and OS (NR vs. NR; p = 0.45) showed a superior tendency in the I-RCHOP group (Fig. 2c and d). In patients aged older than 65 years, the
survival benefit was lower in the I-RCHOP group because of the large number of patients terminated during the initial treatment (Figs. 2e, f, and 3).

**Univariate and multivariate analysis of I-RCHOP**

Univariate and multivariate analyses were performed to determine the predictive factors of I-RCHOP from the Cox proportional hazards model analysis of PFS according to baseline characteristics. The results of univariate analysis revealed worse outcomes in those aged older than 65 years (HR 5.54, 95% CI 1.37–22.38; p = 0.02) and favorable outcomes in those who finished 6 cycles (HR, 0.03; 95% CI, 0.03–0.21; p = 0.00). In multivariate analysis, having completed 6 cycles of chemotherapy was only demonstrated to be an independent prognostic factor for I-RCHOP (HR, 0.02. 95% CI, 0.00–0.21; p = 0.00; Table 5).

### Table 2 Response rate according to age group

|                  | Total patients | Age < 65 years | Age ≥ 65 years | p value |
|------------------|----------------|----------------|----------------|---------|
|                  | n = 24         | n = 16         | n = 8          |         |
| I-RCHOP          |                |                |                |         |
| Overall          | 16             | 14             | 2              | 0.01    |
| Complete response| 16             | 14             | 2              | 0.01    |
| Progression      | 3              | 1              | 2              |         |
| Not evaluable    | 5              | 1              | 4              |         |
| RCHOP            |                |                |                |         |
| Overall          | 16             | 12             | 4              | 0.54    |
| Complete response| 15             | 11             | 4              | 0.70    |
| Partial response | 1              | 1              | 0              |         |
| Progression      | 4              | 2              | 2              |         |
| Not evaluable    | 4              | 2              | 2              |         |

### Table 3 Response rate according to I-RCHOP and R-CHOP

|                  | I-RCHOP n = 24 | RCHOP n = 24 | P-value |
|------------------|----------------|--------------|---------|
| Response to treatment |                |              |         |
| Overall response  | 16             | 16           | 1.00    |
| Complete response | 16             | 15           | 1.00    |
| Partial response  | 0              | 1            |         |
| Progressive disease | 3              | 4            |         |
| Not evaluated     | 5              | 4            |         |
| n = 16            |                |              |         |
| ≪ 65 years        |                |              |         |
| Overall response  | 14             | 12           | 0.69    |
| Complete response | 14             | 11           | 0.53    |
| Partial response  | 0              | 1            |         |
| Progressive disease | 1              | 2            |         |
| Not evaluated     | 1              | 2            |         |
| n = 8             |                |              |         |
| ≧ 65 years        |                |              |         |
| Overall response  | 2              | 4            | 0.81    |
| Complete response | 2              | 4            | 0.81    |
| Progressive disease | 2              | 2            |         |
| Not evaluated     | 4              | 2            |         |
Fig. 2 Kaplan-Meier analyses of PFS (a) and OS (b) according to I-RCHOP and RCHOP in patients with EBV-positive DLBCL; comparison of PFS (c) and OS (d) of I-RCHOP and RCHOP in patients younger than 65; comparison of PFS (e) and OS (f) of I-RCHOP and RCHOP in patients older than 65 years.
Discussion

The previous reported studies about EB-positive DLBCL have suggested that EBV could encourage an inferior outcome in DLBCL [1–4]. EBV using the host’s BCR-mediated protein tyrosine kinase can prevent apoptosis and stimulate the proliferation of infected cells, leading to lymphomagenesis [5, 12, 13]. Based on previous findings, we attempted to combine ibrutinib and RCHOP to improve the outcome of EBV-positive DLBCL. The current study (IVORY) revealed a limited improvement in response and survival in those aged younger than 65 years, while the treatment was associated with severe toxicity in those aged older than 65 years. Although EBV positive was expected to be a potent marker to predict response of BTK inhibitor, the therapeutic efficacy of I-RCHOP in the real world showed less than expected. Thus,

Table 5 Univariate and multivariate analysis of I-RCHOP for estimating prognostic factors

| Variable                  | Univariate | Multivariate |
|---------------------------|------------|--------------|
|                           | HR         | 95% CI       | p value | HR         | 95% CI       | p value |
| Male sex                  | 1.03       | 0.26–4.12    | 0.97    | 0.61       | 0.12–3.19    | 0.55    |
| Age ≥ 65 years            | 5.54       | 1.37–22.38   | 0.02    |            |              |         |
| ECOG ≥ 2                  | 1.46       | 0.66–3.26    | 0.35    |            |              |         |
| Stage ≥ 3                 | 1.62       | 0.34–7.79    | 0.55    |            |              |         |
| B-symptom                 | 1.35       | 0.30–6.07    | 0.70    |            |              |         |
| Extranodal involvement    | 0.45       | 0.05–3.80    | 0.46    |            |              |         |
| IPI ≥ 3                   | 4.24       | 0.88–20.56   | 0.07    |            |              |         |
| Bulky mass ≥ 10 cm        | 4.34       | 0.87–21.74   | 0.07    |            |              |         |
| Finished 6 cycles         | 0.03       | 0.03–0.21    | 0.00    | 0.02       | 0.00–0.21    | 0.00    |

ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index
it was figured out that being EBV-positive was not enough to be a prognostic marker of the BTK inhibitor in the real world.

In our study, including a comparison of I-RCHOP versus RCHOP for EBV-positive DLBCL, the response and survival outcomes cannot support the superiority of I-RCHOP. In patients over the age of 65 years, I-RCHOP showed a lower response rate due to the high rate of early termination (50.0%) caused by severe drug-related toxicity such as sepsis, brain abscess, and meningitis. However, in the age group of those younger than 65 years, I-RCHOP achieved a higher CR as a consequence survival curve of I-RCHOP was presented above that of RCHOP. Although caution should be taken when interpreting our results due to the small number of patients in our findings, as reported by Cox proportional hazards model analysis of PFS, I-RCHOP led to a better prognosis in patients younger than 65 years and with the completion of 6 cycles of chemotherapy (Table 4). Elsewhere, a randomized phase III study (PHOENIX) evaluated I-RCHOP in non-GCB DLBCL. The younger patients (aged < 60 years) with I-RCHOP obtained superior EFS, PFS, and OS as compared with RCHOP plus placebo, and older patients (aged > 60 years) experienced early discontinuation of I-RCHOP chemotherapy due to rates of severe AEs and worse outcomes [14]. These results imply that the patient’s age should be taken into consideration before applying I-RCHOP. For younger patients with non-GCB or EBV-positive DLBCL, ibrutinib could be considered as one of the methods to improve survival.

Park et al. demonstrated that non-neutropenic opportunistic infection after the administration of RCHOP might be associated with the depletion of B cells and impaired humoral immune due to repeated doses of rituximab [15]. The most frequent causes of fever without neutropenia were interstitial pneumonia without bacteremia followed by catheter-related infection mainly occurring at 4 cycles in. In addition, causes of opportunistic infection included Candida, Pneumocystis jirovecii, Cytomegalovirus, and Mycobacterium avium.

Among 24 patients who received I-RCHOP in this study, four experienced severe infection in absence of fever without neutropenia before 4 cycles of chemotherapy (Supplementary Table S2). There was one case of invasive pulmonary aspergillosis, which was not observed in the control group (Fig. 1). Aspergillosis that was only seen in patients older than 60 years of age in PHOENIX trial was reported in six cases in I-RCHOP group, but it also occurred in 2 patients received RCHOP [16, 17]. The previous studies showed that the elimination of aspergillosis occurs by phagocytosis involving the Toll-like receptor 9-BTK-calciineurin-nuclear factor of T cell pathway [18]. Inhibiting the BTK pathway suggests that it could lead to impairment in the adaptive and innate immune systems with fungal infection. However, the recent study reported the most infections during ibrutinib treatment are bacterial and viral infection [19].

In a pooled analysis of 4 randomized trials in CLL and MCL, the reported incidence of fungal infection in ibrutinib was 7%, which was similar to it in comparator arm (6%) [20]. Therefore, we should consider prophylaxis according to standard of care in subjects who are at increased risk for opportunistic infections.

In conclusion, I-RCHOP, which was proposed as a method to avoiding a worse outcome of EBV-positive DLBCL, did not yield a better outcome than RCHOP.

Funding information This study was supported in part by a grant from Janssen Pharmaceuticals. However, Janssen did not have any input regarding the content or interpretation of the study.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS (2007) The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110:972–978
2. Ok CY, Papathomas TG, Medeiros LJ, Young KH (2013) EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 122:328–340
3. Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M, Hills RK, Jaffe ES (2011) Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 117:4726–4735
4. Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS (2015) EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol 26:548–555
5. Kang MS, Kieff E (2015) Epstein-Barr virus latent genes. Exp Mol Med 47:e131
6. Craxton A, Jiang A, Kurosaki T, Clark EA (1999) Syk and Bruton’s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J Biol Chem 274:30644–30650
7. Advani RH, Buggy JJ, Sharanan JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity
in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88–94
8. Younes A, Thiebmont C, Morschauser F, Flinn I, Friedberg JW, Amorim S, Hvert B, Westin J, Vermeulen J, Bandypadhyay N, de Vries R, Balasubramanian S, Hellemons P, Smit JW, Fourneau N, Oki Y (2014) Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 15:1019–1026
9. Cheson BD, Fisher RJ, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer/Dutch Hemato-Oncology G, Grupo Espanol de Medula O, German High-Grade Lymphoma Study G, German Hodgkin’s Study G, Japanese Lymphoma Study G, Lymphoma Study A, NationalCT, Nordic Lymphoma Study G, Southwest Oncology G, United Kingdom National Cancer Research I (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068
10. Younes A, Flinn I, Berdeja J, Friedberg JW, Casulo C, Thiebmont C, Morschauser F, Westin JR, Seetharam S, Hellemons P, Smit H, de Vries R, Dauphinee E, CCRP, Badamo-Dotzis J, Fourneau N, Oki Y (2013) Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naive patients with CD20-positive B-cell non-Hodgkin’s Lymphoma (NHL). Blood 122:852
11. Fleiss JL (1981) Statistical methods for rates and proportions. Wiley, New York, pp 13–15
12. Tempora I, Lieberman PM (2014) Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 26:22–29
13. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328–1337
14. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, Mcclurey J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922–926
15. Park S, Kang CI, Chung DR, Peck KR, Kim WS, Kim SJ (2015) Clinical significance of non-neutropenic fever in the management of diffuse large b-cell lymphoma patients treated with rituximab-CHOP: comparison with febrile neutropenia and risk factor analyses. Cancer Res Treat 47:448–457
16. Ghez D, Calleja A, Procin B, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus F, Ferrant E, Herbaux C, Larbi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graezczyk M, Delavigne K, Dartigues C, Ysebaert L, French Innovative Leukemia Organization CLLg (2018) Early-onset aggressive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 131:1955–1959
17. Chamalis G, Lionakis MS, Kontoyiannis DP (2018) Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis 66:140–148
18. Herbst S, Shah A, Mazon Moya M, Marzola V, Jensen B, Reed A, Birrell MA, Saji Si, Mostowy S, Shaunak S, Armstrong-James D (2015) Phagocytosis-dependent activation of a TL9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus. EMBO Mol Med 7:240–258
19. Dmitrieva E, Nikitin E, Markova E, Dmitrieva N, Ptushkin V (2019) Infections in CLL patients receiving ibrutinib: incidence and predisposing factors. Hematol 3:523–524
20. O’Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Velentino R (2018) Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 18(6):e15–e25

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Sang Eun Yoon 1 · Seok Jin Kim 1 · Dok Hyun Yoon 2 · Youngil Koh 3 · Yeung-Chul Mun 4 · Young Rok Do 5 · Yoon Seok Choi 6 · Deok Hwan Yang 7 · Min Kyong Kim 8 · Gyeong-Won Lee 9 · Cheolwon Suh 2 · Young Hyeh Ko 10 · Won Seog Kim 1

1 Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, South Korea
2 Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, South Korea
3 Department of Medicine, Ulju Hospital, Hwasun 585-110, South Korea
4 Department of Internal Medicine, Yeungnam University College of Medicine, Daejeon, South Korea
5 Division of Hematology-Oncology, Ewha Womans University Hospital, Seoul, South Korea
6 Department of Pathology, Sungkyunkwan University School of Medicine, Seoul, South Korea